Pendapatan dodolan perusahaan genmab.com (GMAB)

Simbol lan logo merek genmab.com (GMAB)

Genmab A/S maintains a stable cash flow driven by inelastic demand in oncology, as confirmed by the monitoring of the company's sales on GURU.Markets, where the 4.30 metric reflects current dynamics. The business foundation consists of unique antibody patents based on a royalty model. The company is currently transforming its strategy by implementing its own commercial network through active M&A transactions.

GMAB Pendapatan lan volume dodolan Genmab (04.07.2022 - 13.11.2026)

Rincian metrik komprehensif lan analitis Genmab (GMAB)

- rega lan prakiraan konsensus rega:
Rega saham Genmab Corp|GMAB - Bagan rega target
- rincian kapitalisasi pasar:
Nilai pasar Genmab A/S|GMAB - Nilai Perusahaan
- indikator nilai aset resik miturut neraca:
Nilai Buku Siji Saham Genmab|GMAB - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku genmab.com|GMAB - Gunggung Aset Perusahaan
- informasi babagan utang lan solvabilitas:
Utang Agregat marang Modal Genmab A/S|GMAB - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Genmab AS|GMAB - Gunggung utang perusahaan|Rasio utang marang nilai buku Genmab A/S|GMAB - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Genmab|Rasio likuiditas perantara genmab.com
- data bathi lan kelipatan valuasi:
GMAB - Bathi resik|Penghasilan resik sing dikarepake Genmab A/S|GMAB - Pangali P/E|Rasio prakiraan rega marang bathi genmab.com|GMAB - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Genmab A/S|GMAB - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Genmab|GMAB - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan genmab.com|GMAB - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham ing taun ngarep Genmab A/S
- statistik dodolan lan pendapatan perusahaan:
GMAB - Pendapatan lan volume dodolan|Prakiraan dodolan perusahaan Genmab Corp|GMAB - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genmab A/S
Ringkesan analisis perusahaan:Genmab Corp GMAB
Produk dadi Genmab A/S

Sales record daily revenue from product realization, determining current market demand. Analyzing the company's aggregate sales figures allows for the identification of anomalies in cash flows. The stability of this metric confirms the operational resilience and financial reliability of the issuer. For Genmab A/S (GMAB), profitability depends on the commercialization of antibodies. However, the automation of synthesis via AI does not eliminate the impact of lengthy clinical trials on the dynamics of inflows.

Perusahaan pesaing

Pendapatan lan volume dodolan Exelixis Inc.|Pendapatan perusahaan Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan IDYA (IDEAYA Biosciences, Inc.)|Total volume dodolan perusahaan Enliven Therapeutics Inc|ORIC Pharma - Pendapatan lan volume dodolan|Total pendapatan perusahaan Relay Corp|NRIX (Nurix Therapeutics) - Dodolan perusahaan|TYRA: Total dodolan perusahaan|VSTM (Verastem) - Pendapatan lan volume dodolan|Total pendapatan perusahaan Monte Rosa Therapeutics Inc GLUE|Pendapatan lan volume dodolan CGEM|Immuneering Corp. - Volume dodolan perusahaan|C4 Therapeutics, Inc. - Dodolan perusahaan|Pendapatan dodolan perusahaan BDTX|RPTX: Dodolan perusahaan|PMV Pharmaceuticals Inc. - Total dodolan perusahaan|KPTI: Pendapatan lan volume dodolan|Propanc Biopharma - Pendapatan dodolan perusahaan|BGMS (Bio Green Med Solution Inc) - Pendapatan lan volume dodolan|Total pendapatan perusahaan Aadi Bio AADI|Pendapatan perusahaan Aileron Therapeutics (ALRN)|BPMC (blueprintmedicines.com) - Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan GLYC (GlycoMimetics)|Pendapatan lan volume dodolan SpringWorks Therapeutics, Inc SWTX